Education
About Us
Working with TipRanks
Follow Us
Invion (AU:IVX)
ASX:IVX
IVX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.20
Previous CloseN/A
Volume36.17K
Average Volume (3M)97.01K
Market Cap
AU$7.19M
Enterprise ValueAU$6.34M
Total Cash (Recent Filing)AU$850.37K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding85,647,255
10 Day Avg. Volume121,261
30 Day Avg. Volume97,006
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Photodynamic Therapy PlatformOwnership of a platform (Photosoft™) focused on light-activated compounds gives Invion a durable R&D asset. Platform approaches can generate multiple candidates across indications, enabling licensing, partnerships or multi-product development, which supports long-term strategic optionality.
Low Financial LeverageA clean balance sheet with no reported debt lowers fixed financing obligations and bankruptcy risk, giving management flexibility to raise capital or pursue partnerships. This structural strength is valuable while the company advances preclinical programs that require intermittent funding.
Focused Preclinical R&D And Lean TeamA small, concentrated R&D organization focused on preclinical development can reduce overhead and accelerate decision cycles. Over the medium term this lean structure may allow more efficient allocation of limited cash toward milestone-driven science and candidate advancement.
Bears Say
Zero Revenue And Widening Net LossesAbsence of revenue combined with materially larger net losses indicates the business is not yet self-sustaining. Persistent losses erode equity, limit reinvestment capacity, and increase reliance on external capital, making long-term R&D plans contingent on successful fundraising or partnering.
Persistent Negative Operating Cash Flow (cash Burn)Consistent negative operating cash flow and negative free cash flow show the company is consuming cash to fund operations. This structural cash burn shortens runway for preclinical work, raises financing and dilution risk, and constrains the ability to progress clinical programs without external funding.
Material Balance Sheet ContractionSignificant declines in equity and assets reflect value erosion from operating losses and weaken the company’s financial buffer. A smaller asset base reduces collateral capacity and may impair access to non-dilutive financing, increasing medium-term financial vulnerability if losses persist.
Invion News
IVX FAQ
What was Invion’s price range in the past 12 months?
Invion lowest share price was AU$0.07 and its highest was AU$0.20 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is AU$7.19M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Mar 04, 2026 which is in 27 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Aug 27, 2025. The company reported -AU$0.094 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.094.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 85,647,255 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -AU$0.094 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.043%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in AU:IVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IVX Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
-74.92%
Trailing 12-Months
Asset Growth
-39.74%
Trailing 12-Months
Company Description
Invion
Invion (IVX) is a biotechnology company focused on the research, development, and commercialization of Photodynamic Therapy (PDT) for the treatment of various cancers. Operating primarily in the healthcare and pharmaceutical sectors, Invion is dedicated to advancing its novel technologies to offer innovative treatment solutions that can improve patient outcomes. The company's core products include its proprietary PDT compounds and related systems that leverage light-activated processes to target and destroy cancer cells.
Technical Analysis
Options Prices
Currently, No data available
---